{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:15Z","timestamp":1790957715991,"version":"4.1.0"},"reference-count":153,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe hereditary arrhythmia syndrome predominantly affecting children and young adults. It manifests through bidirectional or polymorphic ventricular arrhythmia, often culminating in syncope triggered by physical exertion or emotional stress which can lead to sudden cardiac death. Most cases stem from mutations in the gene responsible for encoding the cardiac ryanodine receptor (RyR2), or in the Calsequestrin 2 gene (CASQ2), disrupting the handling of calcium ions within the cardiac myocyte sarcoplasmic reticulum. Diagnosing CPVT typically involves unmasking the arrhythmia through exercise stress testing. This diagnosis emerges in the absence of structural heart disease by cardiac imaging and with a normal baseline electrocardiogram. Traditional first-line treatment primarily involves \u03b2-blocker therapy, significantly reducing CPVT-associated mortality. Adjunctive therapies such as moderate exercise training, flecainide, left cardiac sympathetic denervation and implantable cardioverter-defibrillators have been utilized with reasonable success. However, the spectrum of options for managing CPVT has expanded over time, demonstrating decreased rates of arrhythmic events. Furthermore, ongoing research into potential new therapies including gene therapies has the potential to further enhance treatment paradigms. This review aims to succinctly encapsulate the contemporary understanding of the clinical characteristics, diagnostic approach, established therapeutic interventions and the promising future directions in managing CPVT.<\/jats:p>","DOI":"10.3390\/jcm13061781","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T09:14:33Z","timestamp":1710926073000},"page":"1781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-6390","authenticated-orcid":false,"given":"Abhinav","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-3914","authenticated-orcid":false,"given":"Anton","family":"Stolear","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Mashiul","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarnima","family":"Vardhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Dulgher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nuvance Health, Norwalk Hospital, Norwalk, CT 06856, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Joo","family":"Jang","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06519, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart W.","family":"Zarich","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0002-8703(60)90128-9","article-title":"Multifocal ventricular extrasystoles with Adams-Stokes syndrome in siblings","volume":"60","author":"Berg","year":"1960","journal-title":"Am. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/hrt.37.3.339","article-title":"Bidirectional tachycardia in a child. A study using His bundle electrography","volume":"37","author":"Reid","year":"1975","journal-title":"Br. Heart J."},{"key":"ref_3","first-page":"28","article-title":"Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: Report of four cases","volume":"40","author":"Coumel","year":"1978","journal-title":"Br. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/S0735-1097(99)00461-1","article-title":"Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts","volume":"34","author":"Swan","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/01.CIR.103.2.196","article-title":"Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia","volume":"103","author":"Priori","year":"2001","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCEP.114.002321","article-title":"Management of ventricular arrhythmias in suspected channelopathies","volume":"8","author":"Obeyesekere","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mariani, M.V., Pierucci, N., Fanisio, F., Laviola, D., Silvetti, G., Piro, A., La Fazia, V.M., Chimenti, C., Rebecchi, M., and Drago, F. (2024). Inherited Arrhythmias in the Pediatric Population: An Updated Overview. Medicina, 60.","DOI":"10.3390\/medicina60010094"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1161\/01.CIR.0000144471.98080.CA","article-title":"Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes","volume":"110","author":"Choi","year":"2004","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4065\/79.11.1380","article-title":"Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: A molecular autopsy of 49 medical examiner\/coroner\u2019s cases","volume":"79","author":"Tester","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.0000020013.73106.D8","article-title":"Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia","volume":"106","author":"Priori","year":"2002","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCEP.112.970517","article-title":"Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: Disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives","volume":"5","author":"Nederend","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1253\/circj.CJ-16-0326","article-title":"Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"80","author":"Lieve","year":"2016","journal-title":"Circ. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1161\/CIRCULATIONAHA.111.055947","article-title":"Sudden cardiac death and genetic ion channelopathies: Long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation","volume":"125","author":"Napolitano","year":"2012","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e017128","DOI":"10.1161\/JAHA.120.017128","article-title":"Novel RyR2 Mutation (G3118R) Is Associated with Autosomal Recessive Ventricular Fibrillation and Sudden Death: Clinical, Functional, and Computational Analysis","volume":"10","author":"Shauer","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1113\/JP276757","article-title":"Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia","volume":"598","author":"Wleklinski","year":"2020","journal-title":"J. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.hrthm.2009.06.033","article-title":"Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation","volume":"6","author":"Cerrone","year":"2009","journal-title":"Heart Rhythm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.RES.0000235869.50747.e1","article-title":"Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model","volume":"99","author":"Liu","year":"2006","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia","volume":"119","author":"Hayashi","year":"2009","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/CIRCULATIONAHA.115.015731","article-title":"Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation","volume":"131","author":"Dusi","year":"2015","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCRESAHA.110.226845","article-title":"Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis","volume":"108","author":"Priori","year":"2011","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e126112","DOI":"10.1172\/jci.insight.126112","article-title":"Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Nakamura","year":"2019","journal-title":"JCI Insight"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbrc.2010.03.046","article-title":"Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction","volume":"394","author":"Xu","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.hrthm.2017.12.017","article-title":"EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2","volume":"15","author":"Klipp","year":"2018","journal-title":"Heart Rhythm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jacc.2009.08.022","article-title":"The RYR2-encoded ryanodine receptor\/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: A comprehensive open reading frame mutational analysis","volume":"54","author":"Bhuiyan","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/heartjnl-2021-320220","article-title":"Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1","volume":"108","author":"Shimamoto","year":"2022","journal-title":"Heart"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.jacc.2020.12.073","article-title":"Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5\/5","volume":"77","author":"Priori","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehab687","article-title":"Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death","volume":"43","author":"Walsh","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.120.045723","article-title":"An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"142","author":"Ng","year":"2020","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"148012","DOI":"10.1016\/j.gene.2023.148012","article-title":"Catecholaminergic polymorphic ventricular tachycardia (and seizure) caused by a novel homozygous likely pathogenic variant in CASQ2 gene","volume":"895","author":"Askarinejad","year":"2024","journal-title":"Gene"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Coll, M., Perez-Serra, A., Mates, J., Del Olmo, B., Puigmule, M., Fernandez-Falgueras, A., Iglesias, A., Pico, F., Lopez, L., and Brugada, R. (2017). Incomplete Penetrance and Variable Expressivity: Hallmarks in Channelopathies Associated with Sudden Cardiac Death. Biology, 7.","DOI":"10.3390\/biology7010003"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2004.028993","article-title":"Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients","volume":"42","author":"Postma","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102281","DOI":"10.1016\/j.fsigen.2020.102281","article-title":"Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis?","volume":"47","author":"Mates","year":"2020","journal-title":"Forensic Sci. Int. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Marjamaa, A., Laitinen-Forsblom, P., Lahtinen, A.M., Viitasalo, M., Toivonen, L., Kontula, K., and Swan, H. (2009). Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia. BMC Med. Genet., 10.","DOI":"10.1186\/1471-2350-10-12"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/europace\/eut382","article-title":"Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction","volume":"16","author":"Ohno","year":"2014","journal-title":"EP Europace"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/ajmg.a.37140","article-title":"Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest","volume":"167","author":"Campbell","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41431-018-0119-1","article-title":"Role of copy number variants in sudden cardiac death and related diseases: Genetic analysis and translation into clinical practice","volume":"26","author":"Mates","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.joa.2017.07.007","article-title":"Syncope in patients with inherited arrhythmias","volume":"33","author":"Nakano","year":"2017","journal-title":"J. Arrhythm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.joa.2017.07.005","article-title":"Syncope and the risk of sudden cardiac death: Evaluation, management, and prevention","volume":"33","author":"Koene","year":"2017","journal-title":"J. Arrhythm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1540-8167.2011.02138.x","article-title":"A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia","volume":"23","author":"Richter","year":"2012","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pace.12574","article-title":"Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects","volume":"38","author":"Blich","year":"2015","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/heart.89.1.66","article-title":"Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death","volume":"89","author":"Sumitomo","year":"2003","journal-title":"Heart"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCEP.111.965947","article-title":"How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Obeyesekere","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.hrthm.2011.01.048","article-title":"Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Sy","year":"2011","journal-title":"Heart Rhythm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacep.2021.02.013","article-title":"Burst Exercise Testing Can Unmask Arrhythmias in Patients with Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"7","author":"Roston","year":"2021","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jacep.2023.11.012","article-title":"The Relationship Between Ventilatory Anaerobic Threshold and Arrhythmia in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"10","author":"Aronoff","year":"2024","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e007471","DOI":"10.1161\/CIRCEP.119.007471","article-title":"Heart Rate Recovery After Exercise Is Associated with Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"13","author":"Lieve","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"Kannankeril","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/europace\/eup448","article-title":"High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening","volume":"12","author":"Haugaa","year":"2010","journal-title":"EP Europace"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1540-8167.2011.02188.x","article-title":"Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia","volume":"23","author":"Marjamaa","year":"2012","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.hrthm.2011.05.020","article-title":"HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)","volume":"8","author":"Ackerman","year":"2011","journal-title":"Heart Rhythm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.mayocp.2017.01.015","article-title":"Precision Cardiovascular Medicine: State of Genetic Testing","volume":"92","author":"Giudicessi","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.hrthm.2013.07.021","article-title":"Executive summary: HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e002510","DOI":"10.1161\/CIRCGEN.119.002510","article-title":"Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance","volume":"12","author":"Giudicessi","year":"2019","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.mayocp.2012.02.017","article-title":"Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing","volume":"87","author":"Tester","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: Analysis of therapeutic strategies and outcomes from an international multicenter registry","volume":"8","author":"Roston","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"718208","DOI":"10.3389\/fphar.2021.718208","article-title":"Advances in the Molecular Genetics of Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"12","author":"Song","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Roston, T.M., Haji-Ghassemi, O., LaPage, M.J., Batra, A.S., Bar-Cohen, Y., Anderson, C., Lau, Y.R., Maginot, K., Gebauer, R.A., and Etheridge, S.P. (2018). Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205925"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.hrthm.2021.07.061","article-title":"Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia","volume":"18","author":"Kallas","year":"2021","journal-title":"Heart Rhythm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/europace\/euv357","article-title":"Early repolarization pattern: A marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"18","author":"Tulumen","year":"2016","journal-title":"EP Europace"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/europace\/eus031","article-title":"The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands","volume":"14","author":"Hayashi","year":"2012","journal-title":"EP Europace"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.120.045956","article-title":"Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome","volume":"142","author":"Lahrouchi","year":"2020","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/eurheartj\/ehac298","article-title":"Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?","volume":"43","author":"Corrado","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CRD.0000000000000302","article-title":"Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"28","author":"Kim","year":"2020","journal-title":"Cardiol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1017\/S1047951121003413","article-title":"2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients","volume":"31","author":"Shah","year":"2021","journal-title":"Cardiol. Young"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.jacc.2015.09.042","article-title":"Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement from the American Heart Association and American College of Cardiology","volume":"66","author":"Ackerman","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2019.10.013","article-title":"50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)\u2014Time to Explore the Dark Side of the Moon","volume":"29","author":"Pflaumer","year":"2020","journal-title":"Heart Lung Circ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacep.2016.01.020","article-title":"Competitive Sports Participation in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center'\u2019s Early Experience","volume":"2","author":"Ostby","year":"2016","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hrthm.2018.08.025","article-title":"Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"16","author":"Lieve","year":"2019","journal-title":"Heart Rhythm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijcard.2016.02.023","article-title":"Exercise restrictions for patients with inherited cardiac conditions: Current guidelines, challenges and limitations","volume":"209","author":"Patel","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/jce.13713","article-title":"Physical activity restriction for children and adolescents diagnosed with an inherited arrhythmia or cardiomyopathy and its impact on body mass index","volume":"29","author":"Christian","year":"2018","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/europace\/eur277","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: State of the art and future developments","volume":"14","author":"Zwinderman","year":"2012","journal-title":"EP Europace"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"13","author":"Leren","year":"2016","journal-title":"Heart Rhythm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.121.056018","article-title":"An International Multicenter Cohort Study on beta-Blockers for the Treatment of Symptomatic Children with Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"145","author":"Peltenburg","year":"2022","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jamacardio.2022.0219","article-title":"Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia Treated With beta-Blockers","volume":"7","author":"Mazzanti","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/europace\/eux351","article-title":"Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia","volume":"20","author":"Inoue","year":"2018","journal-title":"EP Europace"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/europace\/euaa106","article-title":"Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: Ventricular arrhythmias, channelopathies, and implantable defibrillators: A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology","volume":"23","author":"Heidbuchel","year":"2020","journal-title":"EP Europace"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"euae044","DOI":"10.1093\/europace\/euae044","article-title":"Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia","volume":"26","author":"Peltenburg","year":"2024","journal-title":"EP Europace"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jacep.2017.05.004","article-title":"Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"3","author":"Miyake","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hrthm.2023.03.543","article-title":"An international multicenter cohort study on beta-blocker free treatment strategies for catecholaminergic polymorphic ventricular tachycardia","volume":"20","author":"Neves","year":"2023","journal-title":"Heart Rhythm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1253\/circj.71.1606","article-title":"Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"71","author":"Sumitomo","year":"2007","journal-title":"Circ. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tcm.2014.07.001","article-title":"Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: Risk factor and potential therapeutic target?","volume":"24","author":"Faggioni","year":"2014","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/CIRCEP.111.962027","article-title":"Catecholaminergic polymorphic ventricular tachycardia","volume":"5","author":"Leenhardt","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Danielsen, T.K., Manotheepan, R., Sadredini, M., Leren, I.S., Edwards, A.G., Vincent, K.P., Lehnart, S.E., Sejersted, O.M., Sjaastad, I., and Haugaa, K.H. (2018). Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207100"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/CIRCRESAHA.120.316819","article-title":"RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT","volume":"128","author":"Kryshtal","year":"2021","journal-title":"Circ. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity","volume":"109","author":"Liu","year":"2011","journal-title":"Circ. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/CIRCRESAHA.116.305347","article-title":"The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2","volume":"116","author":"Bannister","year":"2015","journal-title":"Circ. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.123.064786","article-title":"Flecainide Is Associated with a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"148","author":"Bergeman","year":"2023","journal-title":"Circulation"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","article-title":"Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade","volume":"13","author":"Padfield","year":"2016","journal-title":"Heart Rhythm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCEP.110.959916","article-title":"Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Hwang","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_96","first-page":"74","article-title":"A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone","volume":"5","author":"Marx","year":"2019","journal-title":"Hear. Case Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.hrthm.2010.07.004","article-title":"Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice","volume":"7","author":"Katz","year":"2010","journal-title":"Heart Rhythm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hrthm.2007.05.017","article-title":"Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Rosso","year":"2007","journal-title":"Heart Rhythm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1540-8167.2005.40516.x","article-title":"Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations","volume":"16","author":"Swan","year":"2005","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_101","first-page":"1566","article-title":"The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"10","author":"Weisbrod","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/emmm.201100194","article-title":"Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Jung","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1253\/circj.CJ-10-0680","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S\/+) knock-in mouse model","volume":"74","author":"Kobayashi","year":"2010","journal-title":"Circ. J."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Penttinen, K., Swan, H., Vanninen, S., Paavola, J., Lahtinen, A.M., Kontula, K., and Aalto-Setala, K. (2015). Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134746"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa0708006","article-title":"Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia","volume":"358","author":"Wilde","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCEP.112.971754","article-title":"Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation\/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome","volume":"5","author":"Coleman","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/eurheartj\/ehac134","article-title":"Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias","volume":"43","author":"Schwartz","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.hrthm.2009.03.024","article-title":"Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery","volume":"6","author":"Collura","year":"2009","journal-title":"Heart Rhythm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e018371","DOI":"10.1161\/JAHA.120.018371","article-title":"Arrhythmic Risk Profile and Outcomes of Patients Undergoing Cardiac Sympathetic Denervation for Recurrent Monomorphic Ventricular Tachycardia After Ablation","volume":"10","author":"Dusi","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/0002-9149(76)90420-3","article-title":"Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold","volume":"37","author":"Schwartz","year":"1976","journal-title":"Am. J. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(99)02107-8","article-title":"Long QT syndromes and torsade de pointes","volume":"354","author":"Viskin","year":"1999","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1161\/01.RES.40.6.536","article-title":"Effect of stellectomy and vagotomy on ventricular refractoriness in dogs","volume":"40","author":"Schwartz","year":"1977","journal-title":"Circ. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.RES.14.1.44","article-title":"Nonuniform Recovery of Excitability in Ventricular Muscle","volume":"14","author":"Han","year":"1964","journal-title":"Circ. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1161\/01.RES.69.5.1389","article-title":"Single cardiac vagal fiber activity, acute myocardial ischemia, and risk for sudden death","volume":"69","author":"Cerati","year":"1991","journal-title":"Circ. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.RES.68.5.1471","article-title":"Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction","volume":"68","author":"Vanoli","year":"1991","journal-title":"Circ. Res."},{"key":"ref_116","first-page":"441","article-title":"Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia","volume":"45","author":"Aksu","year":"2017","journal-title":"Turk. Kardiyol. Dern. Ars."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.joa.2016.12.004","article-title":"Percutaneous renal sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia","volume":"33","author":"Aksu","year":"2017","journal-title":"J. Arrhythmia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.hrthm.2010.03.046","article-title":"Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: The surgical supraclavicular approach to cervicothoracic sympathectomy","volume":"7","author":"Odero","year":"2010","journal-title":"Heart Rhythm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCEP.115.003159","article-title":"Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"8","author":"Ertresvaag","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"72","author":"Stevenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hrthm.2015.09.010","article-title":"Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications","volume":"13","author":"Postema","year":"2016","journal-title":"Heart Rhythm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1540-8167.2008.01211.x","article-title":"Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation","volume":"19","author":"Pizzale","year":"2008","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1157\/13093988","article-title":"[Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia]","volume":"59","author":"Palanca","year":"2006","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e003440","DOI":"10.1161\/CIRCEP.115.003440","article-title":"Patient Outcomes from a Specialized Inherited Arrhythmia Clinic","volume":"9","author":"Adler","year":"2016","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCEP.113.000170","article-title":"Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: Success depends on substrate","volume":"6","author":"Miyake","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hrthm.2013.10.027","article-title":"Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia","volume":"11","author":"Jarman","year":"2014","journal-title":"Heart Rhythm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.hrthm.2018.06.046","article-title":"Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review","volume":"15","author":"Roston","year":"2018","journal-title":"Heart Rhythm."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/eurheartj\/ehz309","article-title":"Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest","volume":"40","author":"Lieve","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ccep.2023.04.002","article-title":"Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies","volume":"15","author":"Bergeman","year":"2023","journal-title":"Card. Electrophysiol. Clin."},{"key":"ref_130","unstructured":"Ellenbogen, K.A., Wilkoff, B.L., Neal Kay, G., Lau, C., and Auricchio, A. (2017). Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, Elsevier. [5th ed.]."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hrtlng.2023.02.012","article-title":"Implantable cardioverter-defibrillator in patients with inherited arrhythmia syndromes: A systematic review","volume":"60","author":"Medeiros","year":"2023","journal-title":"Heart Lung"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/europace\/eux009","article-title":"High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: A comparison with other inherited primary arrhythmia syndromes","volume":"20","author":"Conte","year":"2018","journal-title":"EP Europace"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacep.2017.07.017","article-title":"Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies","volume":"3","author":"Liu","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Eckert, H., El-Battrawy, I., Veith, M., Roterberg, G., Kowitz, J., Lang, S., Zhou, X., Akin, I., Mugge, A., and Aweimer, A. (2022). Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040536"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.048728","article-title":"Primary Results from the Understanding Outcomes With the S-ICD in Primary Prevention Patients with Low Ejection Fraction (UNTOUCHED) Trial","volume":"143","author":"Gold","year":"2021","journal-title":"Circulation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.hroo.2020.10.002","article-title":"Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes","volume":"1","author":"Lambiase","year":"2020","journal-title":"Heart Rhythm O2"},{"key":"ref_137","first-page":"319","article-title":"[Ablation of a catecholaminergic polymorphic VT and VF originating from Purkinje fibers\u2014A case report]","volume":"65","author":"Szumowski","year":"2007","journal-title":"Kardiol. Pol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCEP.111.966549","article-title":"Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation","volume":"5","author":"Kaneshiro","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/pace.13006","article-title":"Elimination of Ventricular Arrhythmia in Catecholaminergic Polymorphic Ventricular Tachycardia by Targeting \u201cCatecholamine-Sensitive Area\u201d: A Dominant-Subordinate Relationship between Origin Sites of Bidirectional Ventricular Premature Contractions","volume":"40","author":"Shirai","year":"2017","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacep.2017.04.017","article-title":"Effects of Catheter Ablation Targeting the Trigger Beats in Inherited Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"3","author":"Kaneshiro","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e031768","DOI":"10.1161\/JAHA.123.031768","article-title":"Electrophysiological Characteristics and Ablation Outcomes in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"12","author":"Shen","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/cvr\/cvaa107","article-title":"Gene therapy for inherited arrhythmias","volume":"116","author":"Bezzerides","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2015.61","article-title":"Gene therapy to treat cardiac arrhythmias","volume":"12","author":"Bongianino","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.111.263939","article-title":"Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias","volume":"110","author":"Denegri","year":"2012","journal-title":"Circ. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hrthm.2017.03.025","article-title":"Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models","volume":"14","author":"Yadin","year":"2017","journal-title":"Heart Rhythm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e008155","DOI":"10.1161\/JAHA.117.008155","article-title":"Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"7","author":"Liu","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCRESAHA.117.310882","article-title":"Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2)","volume":"121","author":"Bongianino","year":"2017","journal-title":"Circ. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMra1800729","article-title":"A New Class of Medicines through DNA Editing","volume":"380","author":"Porteus","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.118.313369","article-title":"In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"123","author":"Pan","year":"2018","journal-title":"Circ. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1038\/cddis.2013.369","article-title":"CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Lodola","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa0908679","article-title":"Patient-specific induced pluripotent stem-cell models for long-QT syndrome","volume":"363","author":"Moretti","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"101990","DOI":"10.1016\/j.cpcardiol.2023.101990","article-title":"Precision Medicine and Cardiac Channelopathies: Human iPSCs Take the Lead","volume":"48","author":"Sebastian","year":"2023","journal-title":"Curr. Probl. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:35Z","timestamp":1760105795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":153,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061781"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061781","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}